Disc Medicine, Inc.
IRON- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001816736
In the last 90 days, Disc Medicine, Inc. insiders filed 0 open-market purchases and 9 sales; 216 institutions reported holding it in 13F filings for Q2 2026, worth $3.13B in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Disc Medicine, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 132
- +13 vs. Q2 2024
- Shares held
- 27.4M
- +1.25M (+4.8%) vs. Q2 2024
- Total value
- $1.35B
- +$169.3M (+14.4%) vs. Q2 2024
- New holders
- 25
- 59 more added
- Sold out
- 12
- 26 more reduced
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IRON on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 216 | $3.13B |
| Q1 2026 | 203 | $2.67B |
| Q4 2025 | 197 | $3.04B |
| Q3 2025 | 168 | $2.26B |
| Q2 2025 | 152 | $1.80B |
| Q1 2025 | 157 | $1.65B |
| Q4 2024 | 152 | $1.68B |
| Q3 2024 | 132 | $1.35B |
| Q2 2024 | 121 | $1.24B |
| Q1 2024 | 130 | $1.38B |
| Q4 2023 | 112 | $1.17B |
| Q3 2023 | 91 | $934.0M |
| Q2 2023 | 90 | $848.7M |
| Q1 2023 | 45 | $309.6M |
| Q4 2022 | 35 | $215.8M |
| Q3 2022 | 44 | $43.9M |
| Q2 2022 | 51 | $43.8M |
| Q1 2022 | 57 | $39.6M |
| Q4 2021 | 62 | $93.8M |
| Q3 2021 | 62 | $103.5M |
| Q2 2021 | 55 | $165.3M |
| Q1 2021 | 49 | $346.6M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Disc Medicine, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 160,000 | $7.86M | 0.21% | +160,000 | New |
| Charles Schwab Investment Management Inc | 160,554 | $7.89M | 0.00% | +19,401+13.7% | Added |
| Northern Trust Corp | 170,718 | $8.39M | 0.00% | +72,343+73.5% | Added |
| Goldman Sachs Group Inc | 171,566 | $8.43M | 0.00% | +117,319+216.3% | Added |
| Blue Owl Capital Holdings LP | 175,260 | $8.61M | 1.67% | −40,000−18.6% | Reduced |
| Sio Capital Management, LLC | 187,941 | $9.24M | 4.14% | −4,059−2.1% | Reduced |
| Walleye Capital LLC | 209,236 | $10.3M | 0.11% | +73,140+53.7% | Added |
| Victory Capital Management Inc | 220,014 | $10.8M | 0.01% | −92,035−29.5% | Reduced |
| Foresite Capital Management V, LLC | 299,069 | $14.7M | 10.21% | 00.0% | Unchanged |
| MPM Oncology Impact Management LP | 311,761 | $15.3M | 2.30% | +6,103+2.0% | Added |
| Woodline Partners LP | 377,062 | $18.5M | 0.16% | +109,199+40.8% | Added |
| Perceptive Advisors LLC | 387,017 | $19.0M | 0.41% | −166,420−30.1% | Reduced |
| FMR LLC | 406,814 | $20.0M | 0.00% | −6,283−1.5% | Reduced |
| Citadel Advisors LLC | 411,024 | $20.2M | 0.02% | +89,503+27.8% | Added |
| Geode Capital Management, LLC | 474,719 | $23.3M | 0.00% | +70,983+17.6% | Added |
| TCG Crossover Management, LLC | 486,957 | $23.9M | 2.03% | 00.0% | Unchanged |
| Saturn V Capital Management LLC | 511,041 | $25.1M | 8.98% | +7,952+1.6% | Added |
| Adage Capital Partners GP, L.L.C. | 550,000 | $27.0M | 0.05% | −68,501−11.1% | Reduced |
| Janus Henderson Group PLC | 749,827 | $36.8M | 0.02% | +303,954+68.2% | Added |
| Point72 Asset Management, L.P. | 755,867 | $37.1M | 0.13% | −5,562−0.7% | Reduced |
| State Street Corp | 827,910 | $40.7M | 0.00% | +235,115+39.7% | Added |
| Logos Global Management LP | 935,000 | $45.9M | 5.15% | +10,000+1.1% | Added |
| Deerfield Management Company, L.P. (Series C) | 1,023,265 | $50.3M | 0.75% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,049,530 | $51.6M | 0.00% | −61,894−5.6% | Reduced |
| Price T Rowe Associates Inc | 1,131,947 | $55.6M | 0.01% | +9,753+0.9% | Added |
| Paradigm Biocapital Advisors LP | 1,497,720 | $73.6M | 2.58% | −1,206,998−44.6% | Reduced |
| Frazier Life Sciences Management, L.P. | 1,754,834 | $86.2M | 3.46% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 1,785,571 | $87.7M | 1.61% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 1,795,735 | $88.2M | 9.18% | 00.0% | Unchanged |
| Wellington Management Group LLP | 1,840,226 | $90.4M | 0.02% | +83,731+4.8% | Added |
| BlackRock, Inc. | 1,851,153 | $91.0M | 0.00% | +1,851,153 | New |
| Atlas Venture Life Science Advisors, LLC | 2,509,456 | $123.3M | 11.43% | 00.0% | Unchanged |
| Polar Capital Holdings Plc | 0 | $0 | 0.00% | −244,928−100.0% | Sold out |
| First Turn Management, LLC | 0 | $0 | 0.00% | −138,907−100.0% | Sold out |
| Sphera Funds Management Ltd. | 0 | $0 | 0.00% | −58,044−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −12,300−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −12,103−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −9,475−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −6,642−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −3,331−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −2,400−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −223−100.0% | Sold out |
| nVerses Capital, LLC | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −136−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |
| Institutional & Family Asset Management, LLC | – | – | – | – | Not filed |